MingSight Completes a New Round of Financing to Accelerate Clinical Development in Chronic Lymphocytic Leukemia and Diabetic Macular Edema
SAN DIEGO--(BUSINESS WIRE)--MingSight Pharmaceuticals announced today the close of a pre-Series B round of $20M, led by Kaitai Capital. The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME). “We greatly appreciate the trust and support of our investors,” said Kai Zhang, MD, MBA, CEO and Co-founder of MingSight. “This investment will facil